US 11,945,857 B2
Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
Max D. Cooper, Atlanta, GA (US); Brantley R. Herrin, Decatur, GA (US); and Matthew N. Alder, Birmingham, AL (US)
Assigned to THE UAB RESEARCH FOUNDATION, Birmingham, AL (US)
Filed by THE UAB RESEARCH FOUNDATION, Birmingham, AL (US)
Filed on Dec. 18, 2020, as Appl. No. 17/126,396.
Application 16/265,437 is a division of application No. 15/052,986, filed on Feb. 25, 2016, granted, now 10,239,936, issued on Mar. 26, 2019.
Application 17/126,396 is a continuation of application No. 16/265,437, filed on Feb. 1, 2019, granted, now 10,870,692.
Application 15/052,986 is a continuation of application No. 12/375,804, abandoned, previously published as PCT/US2007/074620, filed on Jul. 27, 2007.
Claims priority of provisional application 60/835,033, filed on Aug. 2, 2006.
Prior Publication US 2021/0253676 A1, Aug. 19, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/12 (2006.01); C07K 16/10 (2006.01); C07K 16/34 (2006.01)
CPC C07K 16/1278 (2013.01) [C07K 16/1018 (2013.01); C07K 16/1063 (2013.01); C07K 16/34 (2013.01); C07K 2317/14 (2013.01); C07K 2317/20 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/76 (2013.01)] 18 Claims
 
1. A cell culture, wherein the culture medium comprises a plurality of multimers comprising a plurality of soluble, monoclonal antigen specific polypeptides, wherein each antigen specific polypeptide comprises an N-terminal leucine rich repeat (LRRNT), one or more leucine rich repeats (LRRs), a C-terminal leucine rich repeat (LRRCT), and a connecting peptide, wherein the connecting peptide comprises an alpha helix.